<rdf:RDF xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:dcterms="http://purl.org/dc/terms/">
<rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6846">
    <dcterms:title><![CDATA[<strong>Storage stability of model infant formula powders produced under varying wet-mix processing conditions</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[SUSTITUTOS DE LA LECHE HUMANA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LECHE HUMANA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LACTANCIA MATERNA]]></dcterms:subject>
    <dcterms:subject><![CDATA[ALIMENTACION INFANTIL]]></dcterms:subject>
    <dcterms:subject><![CDATA[LECHE DE FORMULA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Wet-mixing processes can be tuned to reduce energy consumption, although impacts on quality and stability should be addressed. This work evaluated the effect of wet-mix processing (total solids, TS: 50 or 60%; heat treatment: 75 or 100 C 18 s) and storage conditions (open package: 25 C, 58% RH, 4 weeks; closed package: 25 C, multilayer bag, 12 weeks) on the physicochemical stability and digestibility of infant formulas. Processing significantly influenced the physicochemical characteristics of the powders, with TS exerting a stronger impact than heat treatment. Powders produced from 60% TS wet mixes presented the fastest water sorption, which accelerated lactose crystallisation and fat liberation. Formulas in closed packages were stable for 12 weeks. While lactose crystallised before week 2 in openpackage storage, inducing major physical changes, only limited effects were observed on digestibility. These findings provide valuable insights to ensure consistent quality during shelf-life of infant formula.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Rodr&iacute;guez Arzuaga, Mariana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Abraham, Anal&iacute;a G.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Suescun, Leopoldo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Medrano, Alejandra</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Ahrn&eacute;, Lilia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>D&iacute;az, Marcela</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>B&aacute;ez, Jessica</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>A&ntilde;&oacute;n, Mar&iacute;a Cristina</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">International Dairy Journal, v. 155, 2024. -- e105968</span>]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[12 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.1016/j.idairyj.2024.105968]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6844">
    <dcterms:title><![CDATA[<strong>Hyperthyroidism keeps immunoglobulin levels but reduces milk fat and CD11b/c+ cells on early lactation</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[TIROXINA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LECHE HUMANA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LACTANCIA MATERNA]]></dcterms:subject>
    <dcterms:subject><![CDATA[LEUCOCITOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[ANTICUERPOS]]></dcterms:subject>
    <dcterms:subject><![CDATA[HIPERTIROIDISMO]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2024]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Thyroid hormones influence mammary gland differentiation and lactation by binding to thyroid hormone receptors. Hyperthyroidism disrupts pregnancy and lactation, affecting offspring growth and milk production. Despite maternal milk is a vital source of bioactive compounds and nutrients for newborns, it is unclear whether hyperthyroidism alters its composition, mainly immune factors. Therefore, our work aimed to evaluate the influence of hyperthyroidism on milk quality and immunological parameters during early lactation. Twelve-weekold female Wistar rats received daily injections of 0,25 mg/kg T4 (HyperT, n = 20) or vehicle (control, n = 19) starting 8 days before mating and continuing throughout pregnancy. Rats were euthanized on day 2 of lactation for analyzing the impact of hyperthyroidism on mammary gland, serum and milk samples. HyperT pups exhibited reduced weight, length and head circumference with altered serum hormones, glucose and albumin levels. HyperT mammary gland analysis revealed structural changes, including decreased alveolar area, adipose tissue, increased connective tissue and reduced epithelial elongation, accompanied by decreased TR&beta;1 RNA expression. HyperT milk displayed lower caloric value and fat concentration. HyperT animals exhibited altered milk immune cell counts, displaying increased numbers of CD45+ and CD3+ cells and decreased CD11b/c+ cells without changes on milk and serum IgA, IgG and IgG2a levels. In summary, we have demonstrated that hyperthyroidism affects mammary gland morphology, disrupts pup development and alters biochemical and immunological parameters. Our findings highlight the impact of maternal hyperthyroidism on offspring early development and milk immune composition, underscoring the importance of thyroid function in maternal and neonatal immune health.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>S&aacute;nchez, Mar&iacute;a Bel&eacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Michel Lara, Mar&iacute;a Cecilia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Neira, Flavia Judith</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rodr&iacute;guez-Camejo, Claudio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>R&iacute;os, Juan Manuel</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Viruel, Luciana Bel&eacute;n</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Moreno-Sosa, Mar&iacute;a Tamara</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Pietrobon, Elisa Olivia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Soaje, Marta</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Jahn, Graciela Alma</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hern&aacute;ndez, Ana</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Valdez, Susana Ruth</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Mackern-Oberti, Juan Pablo</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">Molecular and Cellular Endocrinology, v. 594, 2024. -- e112370</span>]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2024]]></dcterms:date>
    <dcterms:rights><![CDATA[<div class="element-text">
<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>
</div>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[13 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[<span data-sheets-formula-bar-text-style="font-size:13px;color:#000000;font-weight:normal;text-decoration:none;font-family:'Arial';font-style:normal;text-decoration-skip-ink:none;">10.1016/j.mce.2024.112370</span>]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6764">
    <dcterms:title><![CDATA[<strong>Effects of human donor milk on gut barrier function and inflammation : in vitro study of the beneficial properties to the newborn</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[BANCOS DE LECHE]]></dcterms:subject>
    <dcterms:subject><![CDATA[LECHE HUMANA]]></dcterms:subject>
    <dcterms:subject><![CDATA[PASTEURIZACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[ENFERMEDADES INTESTINALES]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2023]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Introduction: The gastrointestinal and immune systems of premature infants are not fully developed, rendering them more vulnerable to severe complications like necrotizing enterocolitis. Human milk offers a rich array of bioactive factors that collectively contribute to reducing the incidence of gut infections and inflammatory conditions. When a mother's milk is unavailable, preterm infants are often provided with donor human milk processed in Human Milk Banks. However, it remains uncertain whether pasteurized milk confers the same level of risk reduction as unprocessed milk. This uncertainty may stem from the welldocumented adverse effects of heat treatment on milk composition. Yet, our understanding of the comprehensive impact on protective mechanisms is limited. Methods: In this study, we conducted a comparative analysis of the effects of raw versus pasteurized milk and colostrum versus mature milk on cellular functions associated with the gut epithelial barrier and responses to inflammatory stimuli. We utilized THP-1 and HT-29 cell lines, representing monocyte/macrophages and gut epithelial cells, respectively. Results: Our observations revealed that all milk types stimulated epithelial cell proliferation. However, only raw colostrum increased cell migration and interfered with the interaction between E. coli and epithelial cells. Furthermore, the response of epithelial and macrophage cells to lipopolysaccharide (LPS) was enhanced solely by raw colostrum,with a milder effect observedwith mature milk. In contrast, both raw and pasteurized milk diminished the LPS induced response in monocytes. Lastly, we examined how milk affected the differentiation of monocytes into macrophages, finding that milk reduced the subsequent inflammatory response of macrophages to LPS.Discussion: Our study sheds light on the impact of human milk on certain mechanisms that potentially account for its protective effects against necrotizing enterocolitis, highlighting the detrimental influence of pasteurization on some of these mechanisms. Our findings emphasize the urgency of developing alternative pasteurization methods to better preserve milk properties. Moreover, identifying the key components critically affected by these protective mechanisms could enable their inclusion in donor milk or formula, thereby enhancing immunological benefits for vulnerable newborns.]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Rodr&iacute;guez Camejo, Claudio</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Puyol, Arturo</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Arbildi, Paula</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>S&oacute;&ntilde;ora, Cecilia</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fazio, Laura</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Sir&eacute;, Gabriela</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hern&aacute;ndez, Ana</strong>]]></dcterms:creator>
    <dcterms:publisher><![CDATA[Frontiers in Immunology v. 14, 2023. -- e1282144]]></dcterms:publisher>
    <dcterms:date><![CDATA[2023]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong></p>
<p>(Por favor lea este aviso antes de abrir los documentos u objetos)</p>
<p><strong>La legislaci&oacute;n uruguaya protege el derecho</strong>&nbsp;de autor sobre toda creaci&oacute;n literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA -</strong>&nbsp;La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:extent><![CDATA[17 p.]]></dcterms:extent>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[10.3389/fimmu.2023.1282144]]></dcterms:identifier>
</rdf:Description><rdf:Description rdf:about="https://riquim.fq.edu.uy/items/show/6102">
    <dcterms:title><![CDATA[<strong>High-pressure homogenization and high hydrostatic pressure processing of human milk: Preservation of immunological components for human milk banks</strong>]]></dcterms:title>
    <dcterms:subject><![CDATA[LECHE HUMANA]]></dcterms:subject>
    <dcterms:subject><![CDATA[HOMOGENEIZACION]]></dcterms:subject>
    <dcterms:subject><![CDATA[BANCOS DE LECHE]]></dcterms:subject>
    <dcterms:subject><![CDATA[PRESERVACION INMUNOLOGICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[BIBLIOGRAFIA NACIONAL QUIMICA]]></dcterms:subject>
    <dcterms:subject><![CDATA[2020]]></dcterms:subject>
    <dcterms:abstract><![CDATA[Human milk (HM) constitutes the first immunological barrier and the main source of nutrients and bioactive components for newborns. Immune factors comprise up to 10% of the protein content in HM, where antibodies are the major components (mainly IgA, IgG, and IgM). In addition, antibacterial enzymes such as lysozyme and immunoregulatory factors such as soluble cluster of differentiation 14 (sCD14) and transforming growth factor β2 (TGF-β2) are also present and play important roles in the protection of the infant&#039;s health. Donor milk processed in HM banks by Holder pasteurization (HoP; 62.5°C, 30 min) is a safe and valuable resource for preterm newborns that are hospitalized, but is reduced in major immunological components due to thermal inactivation. We hypothesized that high hydrostatic pressure (HHP) and high-pressure homogenization (HPH) are 2 processes that can be used on HM to reduce total bacteria counts while retaining immunological components. We studied the effects of HHP (400, 450, and 500 MPa for 5 min applied at 20°C) and HPH (200, 250, and 300 MPa, milk inlet temperature of 20°C) applied to mature HM, on microbiological and immunological markers (IgA, IgG, IgM, sCD14, and TGF-β2), and compared them with those of traditional HoP in HM samples from healthy donors. The HHP processing between 400 and 500 MPa at 20°C reduced counts of coliform and total aerobic bacteria to undetectable levels (&lt;1.0 log cfu/mL) while achieving approximately 100% of immunological component retention. In particular, comparing median percentages of retention of immunological components for 450 MPa versus HoP, we found 101.5 versus 50.5% for IgA, 89.5 versus 26.0% for IgM, 104.5 versus 75.5% for IgG, 125.0 versus 72.5% for lysozyme, 50.6 versus 0.1% for sCD14, and 88.5 versus 61.1% for TGF-β2, respectively. Regarding HPH processing, at a pressure of 250 MPa and inlet temperature of 20°C, the process showed good potential to reduce coliforms to undetectable levels and total aerobic bacteria to levels slightly above those obtained by HoP. The median percentages of retention of immunological markers for HPH versus HoP were 71.5 versus 52.0%, 71.0 versus 27.0%, 104.0 versus 66.5%, and 30.9 versus 0.2%, for IgA, IgM, IgG, and sCD14, respectively; results did not significantly differ for lysozyme and TGF-β2. The HPH at 300 MPa produced higher inactivation of immunological components, similar to values achieved with HoP.<br />
<br />
]]></dcterms:abstract>
    <dcterms:creator><![CDATA[<strong>Irazusta, A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Rodr&iacute;guez Camejo, C.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Jorcin, S.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Puyol, A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Fazio, L.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Arias, F.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Castro, M.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>Hern&aacute;ndez, A.</strong>]]></dcterms:creator>
    <dcterms:creator><![CDATA[<strong>L&oacute;pez Pedemonte, T.</strong>]]></dcterms:creator>
    <dcterms:source><![CDATA[Journal of Dairy Science v. 103, 2020. -- p. 5978&ndash;5991]]></dcterms:source>
    <dcterms:publisher><![CDATA[Elsevier]]></dcterms:publisher>
    <dcterms:date><![CDATA[2020]]></dcterms:date>
    <dcterms:rights><![CDATA[<p><strong>Informaci&oacute;n sobre Derechos de Autor</strong> (Por favor lea este aviso antes de abrir los documentos u objetos)<strong> La legislaci&oacute;n uruguaya protege el derecho de autor sobre toda creaci&oacute;n</strong> literaria, cient&iacute;fica o art&iacute;stica, tanto en lo que tiene que ver con sus derechos morales, como en lo referente a los derechos patrimoniales con sujeci&oacute;n a lo establecido por el derecho com&uacute;n y las siguientes leyes (LEY 9.739 DE 17 DE DICIEMBRE DE 1937 SOBRE PROPIEDAD LITERARIA Y ARTISTICA CON LAS MODIFICACIONES INTRODUCIDAS POR LA LEY DE DERECHO DE AUTOR Y DERECHOS CONEXOS No. 17.616 DE 10 DE ENERO DE 2003, LEY 17.805 DE 26 DE AGOSTO DE 2004, LEY 18.046 DE 24 DE OCTUBRE DE 2006 LEY 18.046 DE 24 DE OCTUBRE DE 2006)</p>
<p><strong>ADVERTENCIA</strong> - La consulta de este documento queda condicionada a la aceptaci&oacute;n de las siguientes condiciones de uso: Este documento es &uacute;nicamente para usos privados enmarcados en actividades de investigaci&oacute;n y docencia. No se autoriza su reproducci&oacute;n con fines de lucro. Esta reserva de derechos afecta tanto los datos del documento como a sus contenidos. En la utilizaci&oacute;n o cita de partes debe indicarse el nombre de la persona autora.</p>]]></dcterms:rights>
    <dcterms:format><![CDATA[PDF]]></dcterms:format>
    <dcterms:language><![CDATA[Ingl&eacute;s]]></dcterms:language>
    <dcterms:type><![CDATA[Art&iacute;culo]]></dcterms:type>
    <dcterms:identifier><![CDATA[DOI: 10.3168/jds.2019-17569]]></dcterms:identifier>
</rdf:Description></rdf:RDF>
